Nantahala Capital Management LLC Buys Shares of 450,000 Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Nantahala Capital Management LLC purchased a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 450,000 shares of the company’s stock, valued at approximately $4,064,000. Nantahala Capital Management LLC owned approximately 0.45% of Centessa Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Quarry LP acquired a new position in Centessa Pharmaceuticals in the 4th quarter worth $48,000. Sandia Investment Management LP bought a new stake in Centessa Pharmaceuticals in the 2nd quarter valued at approximately $90,000. Fred Alger Management LLC acquired a new position in Centessa Pharmaceuticals during the 2nd quarter worth approximately $99,000. EntryPoint Capital LLC bought a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $109,000. Finally, Trexquant Investment LP acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $114,000. 82.01% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, CEO Saurabh Saha sold 175,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $16.52, for a total value of $2,891,000.00. Following the completion of the transaction, the chief executive officer now directly owns 776,924 shares of the company’s stock, valued at $12,834,784.48. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 175,000 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $16.52, for a total value of $2,891,000.00. Following the completion of the transaction, the chief executive officer now owns 776,924 shares in the company, valued at approximately $12,834,784.48. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Gregory M. Weinhoff sold 12,198 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total transaction of $148,449.66. Following the completion of the sale, the insider now directly owns 241,171 shares of the company’s stock, valued at $2,935,051.07. The disclosure for this sale can be found here. In the last 90 days, insiders sold 288,492 shares of company stock worth $4,641,902. Insiders own 11.59% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on CNTA shares. BMO Capital Markets lifted their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Jefferies Financial Group raised their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Oppenheimer reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. Finally, B. Riley began coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They issued a “buy” rating and a $33.00 target price for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $25.17.

Centessa Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ CNTA opened at $15.99 on Tuesday. Centessa Pharmaceuticals plc has a 52-week low of $5.15 and a 52-week high of $17.59. The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29. The company’s 50 day moving average price is $13.14 and its 200-day moving average price is $10.88. The company has a market capitalization of $1.61 billion, a P/E ratio of -11.26 and a beta of 1.44.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Equities analysts forecast that Centessa Pharmaceuticals plc will post -1.62 earnings per share for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.